NCT03301090View on ClinicalTrials.gov

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

January 19, 2019

Study Completion Date

January 19, 2019

Conditions
Corona Virus Infection
Interventions
OTHER

Placebo

Placebo

BIOLOGICAL

REGN3048

REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.

BIOLOGICAL

REGN3051

REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.

Trial Locations (1)

90630

WCCT Global Cypress Clinical Pharmacology Unit, Cypress

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03301090 - A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 | Biotech Hunter | Biotech Hunter